Attentional Mechanisms in SCD
ConditionSubjective Cognitive Decline
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age55+
SponsorVanderbilt University Medical Center
About this trial
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
age ≥ 55
Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating < 3
Non-smokers
Disqualifiers
medical contraindications to the drug challenge
primary neurological disorder (such as stroke, epilepsy, etc.)
Trial design
Design model
Crossover
Treatments tested in this trial
Mecamylamine Challenge
DrugMecamylamine 20 mg oral pill administered once
Placebo Comparator Challenge
Other interventionMatching placebo oral pill administered once
Treatment groups
80 Participants
are divided into 2 treatment groupsGroup A: Anticholinergic ChallengeExperimental treatment 1 intervention
Group B: Placebo ChallengePlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Peak P1 amplitude for Orienting
Peak P1 amplitude in parietal regions for Orienting trials of the Attention Network Test (ANT) dyrung anticholinergic challenge
Time frame
After administration of second drug challenge, approximately 72 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov